ProShare Advisors
ELVN icon

ProShare Advisors’s Enliven Therapeutics ELVN Stock Holding History

ProShare Advisors’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$386K Sell
7,606
-753
-9% -$32K ﹤0.01% 1265
2026
Q1 		$328K Buy
+8,359
New +$232K ﹤0.01% 1290
2025
Q2 		– Sell
-10,125
Closed -$199K – 2111
2025
Q1 		$199K Sell
10,125
-2,104
-17% -$45.3K ﹤0.01% 1689
2024
Q4 		$275K Buy
12,229
+2,788
+30% +$72.3K ﹤0.01% 1695
2024
Q3 		$241K Buy
+9,441
New +$219K ﹤0.01% 1615

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

ProShare Advisors's ELVN Position: Q2 2026 in Review

ProShare Advisors reduced its Enliven Therapeutics (ELVN) stake by 9% in Q2 2026, selling an estimated $32K and leaving 7,606 shares worth $386K. The position accounts for ﹤0.01% of the portfolio, ranked #1265.

ProShare Advisors first reported a position in ELVN in Q3 2024 and has held it in 5 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • ProShare Advisors held 7,606 shares of Enliven Therapeutics worth $386K as of Q2 2026.
  • ProShare Advisors sold 753 Enliven Therapeutics shares in Q2 2026, an estimated $32K.
  • Enliven Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #1265 holding.
  • ProShare Advisors first reported a position in Enliven Therapeutics in Q3 2024 and has held it in 5 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.